We propose the 5-year renewal of the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), a consortia of the two leading sister campuses within the University System of Maryland, and the FDA. M-CERSI leverages the engineering, device, and technologies strengths in College Park with the biomedical and health outcomes strengths in Baltimore.
Five Specific Aims are: 1. Establish Core Program Support and Management Plan to Ensure Success; 2. Grow regulatory science training/educational programs; 3. Build Collaborative Interactions to Foster Regulatory Science Communications Including Scientific Exchanges, Workshops and Seminars; 4. Create New Opportunities for Collaborative Regulatory Science Research; and 5. Create Opportunities to Leverage FDA Funds in Support of CERSI Activities. Pilot research projects are proposed that align UM research strengths with six FDA Regulatory Science Initiatives: o Modernize toxicology to enhance product safety o Support new approaches to improve product manufacturing and quality o Ensure FDA readiness to evaluate innovative emerging technologies o Harness diverse data through information sciences to improve health outcomes o Strengthen social and behavioral science to help consumers and professionals make informed decisions about FDA regulated products o Strengthening the global product safety net In addition to their alignment with FDA-wide priority areas, the pilot projects and other M-CERSI activities align well with priority areas specifically noted by CDER, CBER, CDRH, the OMH, OHI, and OWH. The sum of these activities describe a vibrant, cutting edge Center that stimulates innovative thought, disseminates understanding of regulatory sciences and practices, and generates new knowledge in support of the FDA's fundamental mission ? to promote and protect the public health.
We propose continuation of M-CERSI that fosters scientific exchange, education and training, as well as FDA- oriented research, all focused on regulatory science. The Center is organized into six Specific Aims: Establish Core Program Support and Management Plan to Ensure Success; Grow regulatory science training/educational programs; Build Collaborative Interactions to Foster Regulatory Science Communications Including Scientific Exchanges, Workshops and Seminars; Create New Opportunities for Collaborative Regulatory Science Research; Create Opportunities to Leverage FDA Funds in Support of CERSI Activities. Each aim builds a base for interactions between the University of Maryland and the FDA with the objective being to promote the science that underpins FDA regulatory practice.
|Ali, Izna; Welch, Matthew A; Lu, Yang et al. (2017) Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay. Eur J Pharm Sci 103:52-59|
|Dong, Zhongqi; Li, Qing; Guo, Dong et al. (2015) Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver. J Pharm Sci 104:2864-76|
|Dong, Zhongqi; Ekins, Sean; Polli, James E (2015) Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. Eur J Pharm Sci 66:1-9|
|Dong, Zhongqi; Ekins, Sean; Polli, James E (2015) A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide. Int J Pharm 478:88-95|
|González, Pablo M; Lagos, Carlos F; Ward, Weslyn C et al. (2014) Structural requirements of the human sodium-dependent bile acid transporter (hASBT): role of 3- and 7-OH moieties on binding and translocation of bile acids. Mol Pharm 11:588-98|
|Vivian, Diana; Polli, James E (2014) Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver. Int J Pharm 475:597-604|
|Vivian, Diana; Cheng, Kunrong; Khurana, Sandeep et al. (2013) Design and characterization of a novel fluorinated magnetic resonance imaging agent for functional analysis of bile Acid transporter activity. Pharm Res 30:1240-51|
|Kolhatkar, Vidula; Polli, James E (2012) Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups. Eur J Pharm Sci 46:86-99|
|Ekins, Sean; Diao, Lei; Polli, James E (2012) A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis. Mol Pharm 9:905-13|
|Acharya, Chayan; Coop, Andrew; Polli, James E et al. (2011) Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des 7:10-22|
Showing the most recent 10 out of 23 publications